They O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

L-T4 O
was O
initiated O
in O
both O
groups O
after O
thyroidectomy O
. O

Neither B-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
nor I-Claim
FU24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
with I-Premise
DCF I-Premise
versus I-Premise
CF I-Premise
( I-Premise
23 I-Premise
% I-Premise
risk I-Premise
reduction I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim

These O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low-dose O
CDDP O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5-FU O
at O
a O
dose O
of O
300 O
mg/m O
( O
2 O
) O
/24 O
hrs O
in O
a O
one-week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

Secondary B-Premise
analyses I-Premise
found I-Premise
that I-Premise
differences I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
experimental I-Premise
group I-Premise
occurred I-Premise
in I-Premise
patients I-Premise
with I-Premise
stomach I-Premise
, I-Premise
pancreatic I-Premise
, I-Premise
primary I-Premise
liver I-Premise
, I-Premise
or I-Premise
colorectal I-Premise
cancer I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
cumulative I-Premise
survival I-Premise
. I-Premise

From O
January O
2002 O
to O
February O
2004 O
, O
102 O
patients O
who O
had O
undergone O
RP O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1-those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2-those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3-those O
receiving O
bicalutamide O
and O
RT O
. O

Treatment-related B-Premise
mortality I-Premise
occurred I-Premise
in I-Premise
five I-Premise
patients I-Premise
( I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
receiving I-Premise
irinotecan I-Premise
weekly I-Premise
and I-Premise
three I-Premise
patients I-Premise
( I-Premise
1.6 I-Premise
% I-Premise
) I-Premise
given I-Premise
therapy I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.12 I-Premise
) I-Premise
. I-Premise

Advanced O
gastric O
cancer O
patients O
were O
randomly O
assigned O
to O
docetaxel O
75 O
mg/m2 O
and O
cisplatin O
75 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
750 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
3 O
weeks O
or O
cisplatin O
100 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
1,000 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
4 O
weeks O
. O

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

This O
study O
is O
the O
first O
large O
prospective O
RCT O
of O
sentinel O
node O
biopsy O
( O
SNB O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
I-III O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
QOL O
) O
assessments O
over O
18 O
months O
. O

Overall B-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
scores I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
arms I-Premise
at I-Premise
the I-Premise
fourth I-Premise
assessment I-Premise
( I-Premise
C I-Premise
= I-Premise
70.3 I-Premise
( I-Premise
19.6 I-Premise
) I-Premise
";" I-Premise
CP I-Premise
= I-Premise
72.8 I-Premise
( I-Premise
17.4 I-Premise
) I-Premise
) I-Premise
. I-Premise

Regularly O
collecting O
patient-reported O
outcomes O
( O
PROs O
) O
of O
health-related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O

From O
January O
, O
2001 O
, O
until O
August O
, O
2005 O
, O
504 O
patients O
were O
randomly O
assigned O
to O
pamidronate O
30 O
mg O
or O
90 O
mg O
( O
252 O
in O
each O
group O
) O
. O

They B-Premise
deteriorated I-Premise
during I-Premise
follow-up I-Premise
in I-Premise
women I-Premise
not I-Premise
continuing I-Premise
ccHRT I-Premise
. I-Premise

Patients O
14 O
to O
70 O
years O
of O
age O
with O
newly O
diagnosed O
GBM O
and O
Karnofsky O
Performance O
Scale O
( O
KPS O
) O
score O
> O
70 O
who O
were O
receiving O
initial O
treatment O
were O
enrolled O
and O
were O
randomized O
into O
2 O
groups O
during O
the O
5-year O
study O
period O
. O

The B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40.0 I-Premise
% I-Premise
for I-Premise
PT I-Premise
versus I-Premise
37.5 I-Premise
% I-Premise
for I-Premise
TC I-Premise
, I-Premise
difference I-Premise
= I-Premise
2.5 I-Premise
% I-Premise
, I-Premise
one-sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Health-Related O
Quality O
of O
Life O
[ O
RAND-36 O
and O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand-held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O

Costs O
associated O
with O
medical O
care O
resource O
use O
and O
quality-of-life O
adjustments O
were O
obtained O
from O
the O
published O
literature O
. O

Thirty-eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0Â·001 I-Premise
) I-Premise
. I-Premise

Mean O
scores O
of O
individual O
domains/scales O
of O
3D-CRT O
and O
IMRT O
were O
compared O
using O
't O
' O
test O
at O
each O
time O
point O
";" O
while O
longitudinal O
change O
in O
mean O
scores O
of O
both O
groups O
over O
time O
was O
evaluated O
by O
repeated O
measurement O
analysis O
of O
variance O
. O

A B-Premise
multivariate I-Premise
analysis I-Premise
found I-Premise
the I-Premise
use I-Premise
of I-Premise
breast I-Premise
IMRT I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
and I-Premise
smaller I-Premise
breast I-Premise
size I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
a I-Premise
decreased I-Premise
risk I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
. I-Premise

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
";" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Analgesic B-Premise
cost I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
treated I-Premise
groups I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

This O
phase O
III O
study O
investigated O
the O
effect O
of O
combining O
oxaliplatin O
with O
LV5FU2 O
, O
with O
progression-free O
survival O
as O
the O
primary O
end O
point O
. O

Liposomal B-Premise
tretinoin I-Premise
is I-Premise
a I-Premise
new I-Premise
therapeutic I-Premise
agent I-Premise
that I-Premise
has I-Premise
been I-Premise
reported I-Premise
to I-Premise
have I-Premise
some I-Premise
clinical I-Premise
activity I-Premise
in I-Premise
patients I-Premise
with I-Premise
AIDS-associated I-Premise
Kaposi I-Premise
sarcoma I-Premise
. I-Premise

The B-Premise
carboplatin I-Premise
containing I-Premise
regimen I-Premise
( I-Premise
MVC I-Premise
) I-Premise
has I-Premise
a I-Premise
significant I-Premise
better I-Premise
toxicity I-Premise
profile I-Premise
than I-Premise
the I-Premise
cisplatin I-Premise
containing I-Premise
( I-Premise
MVP I-Premise
) I-Premise
regimen I-Premise
as I-Premise
proven I-Premise
both I-Premise
by I-Premise
the I-Premise
EORTC I-Premise
questionnaires I-Premise
and I-Premise
by I-Premise
the I-Premise
WHO I-Premise
toxicity I-Premise
data I-Premise
reported I-Premise
by I-Premise
physicians I-Premise
. I-Premise

Quality O
of O
life O
was O
measured O
by O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
for O
Palliative O
Care O
( O
score O
range O
, O
0-184 O
) O
. O

Gefitinib O
has O
shown O
high O
response O
rate O
and O
improved O
progression-free O
survival O
( O
PFS O
) O
in O
never-smokers O
with O
lung O
adenocarcinoma O
( O
NSLAs O
) O
. O

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

A O
total O
of O
497 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
were O
randomly O
assigned O
to O
receive O
bolus O
FU O
425 O
mg/m2 O
intravenously O
+ O
LV O
20 O
mg/m2 O
on O
days O
1 O
to O
5 O
and O
repeated O
on O
day O
28 O
( O
FU O
+ O
LV O
) O
, O
or O
FU O
2600 O
mg/m2 O
as O
a O
24-hour O
infusion O
alone O
( O
FU24h O
) O
or O
in O
combination O
with O
500 O
mg/m2 O
LV O
( O
FU24h O
+ O
LV O
) O
-all O
given O
weekly O
x6 O
followed O
by O
a O
2-week O
rest O
period O
. O

The B-Claim
use I-Claim
of I-Claim
spherical I-Claim
PVA I-Claim
particles I-Claim
in I-Claim
the I-Claim
manner I-Claim
described I-Claim
herein I-Claim
results I-Claim
in I-Claim
an I-Claim
unacceptably I-Claim
high I-Claim
rate I-Claim
of I-Claim
failed I-Claim
tumor I-Claim
infarction I-Claim
in I-Claim
UAE I-Claim
. I-Claim

Study O
follow-up O
was O
completed O
July O
2012 O
. O

Radiation-induced O
mucositis O
is O
an O
acute O
reaction O
of O
the O
mucosa O
of O
patients O
undergoing O
head O
and O
neck O
radiotherapy O
. O

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
more I-Premise
treatment I-Premise
cycles I-Premise
with I-Premise
docetaxel I-Premise
( I-Premise
TC I-Premise
, I-Premise
49 I-Premise
% I-Premise
";" I-Premise
TCF I-Premise
, I-Premise
57 I-Premise
% I-Premise
";" I-Premise
ECF I-Premise
, I-Premise
34 I-Premise
% I-Premise
) I-Premise
. I-Premise

This B-Claim
supports I-Claim
the I-Claim
need I-Claim
for I-Claim
an I-Claim
individualized I-Claim
approach I-Claim
to I-Claim
therapy I-Claim
recommendations I-Claim
. I-Claim

The B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Also O
, O
the B-Premise
Kaplan-Meier I-Premise
survival I-Premise
curves I-Premise
of I-Premise
these I-Premise
two I-Premise
groups I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
by I-Premise
log-rank I-Premise
test I-Premise
( I-Premise
p=0.286 I-Premise
) I-Premise
. I-Premise

From B-Premise
cycle I-Premise
5 I-Premise
onwards I-Premise
, I-Premise
improvements I-Premise
relative I-Premise
to I-Premise
baseline/MP I-Premise
were I-Premise
observed I-Premise
for I-Premise
all I-Premise
domains I-Premise
with I-Premise
VMP I-Premise
. I-Premise

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Anemia I-Premise
( I-Premise
FACT-An I-Premise
";" I-Premise
mean I-Premise
, I-Premise
2.16 I-Premise
+/- I-Premise
12.84 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
-4.43 I-Premise
+/- I-Premise
13.42 I-Premise
for I-Premise
SOC I-Premise
) I-Premise
and I-Premise
FACT-An I-Premise
fatigue I-Premise
( I-Premise
mean I-Premise
, I-Premise
1.85 I-Premise
+/- I-Premise
10.52 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
-3.55 I-Premise
+/- I-Premise
11.14 I-Premise
for I-Premise
SOC I-Premise
) I-Premise
change I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post-treatment I-Claim
. I-Claim

MBSR B-Claim
is I-Claim
recommended I-Claim
to I-Claim
support I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
";" I-Premise
TC-Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i.e. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
61.4 I-Premise
% I-Premise
to I-Premise
76.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
and I-Premise
76.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
69.3 I-Premise
% I-Premise
to I-Premise
83.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.166 I-Premise
) I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
significantly I-Claim
improved I-Claim
HgB I-Claim
and I-Claim
reduced I-Claim
transfusions I-Claim
in I-Claim
this I-Claim
patient I-Claim
population I-Claim
. I-Claim

However B-Claim
, I-Claim
combination I-Claim
modalities I-Claim
including I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
may I-Claim
be I-Claim
the I-Claim
preferred I-Claim
choices I-Claim
for I-Claim
their I-Claim
applicability I-Claim
at I-Claim
home I-Claim
. I-Claim

Radiation B-Claim
therapy I-Claim
for I-Claim
prostate I-Claim
carcinoma I-Claim
causes I-Claim
persistent I-Claim
GI I-Claim
toxicity I-Claim
that I-Claim
is I-Claim
largely I-Claim
independent I-Claim
of I-Claim
the I-Claim
two I-Claim
dose I-Claim
schedules I-Claim
. I-Claim

CONNECT B-Claim
has I-Claim
shown I-Claim
promising I-Claim
indications I-Claim
on I-Claim
health I-Claim
system I-Claim
and I-Claim
patient I-Claim
outcomes I-Claim
that I-Claim
warrant I-Claim
a I-Claim
larger I-Claim
study I-Claim
to I-Claim
further I-Claim
investigate I-Claim
the I-Claim
potential I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

Subcutaneous B-Claim
interleukin-2 I-Claim
and/or I-Claim
interferon-alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

The B-Claim
3-hour I-Claim
infusion I-Claim
of I-Claim
Taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim

Docetaxel B-Claim
has I-Claim
shown I-Claim
activity I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

However B-Claim
, I-Claim
its I-Claim
safety I-Claim
should I-Claim
be I-Claim
confirmed I-Claim
by I-Claim
the I-Claim
results I-Claim
of I-Claim
larger I-Claim
randomized I-Claim
trials I-Claim
and I-Claim
meta-analyses I-Claim
. I-Claim

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

